In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Medivation (MDVN) with a $112 price target. The report follows Medivation’s partner Astellas (ALPMY) second quarter results that included US …
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Pluristem Therapeutics (PSTI) with a $8 price target, which represents a potential upside of 176% from …
Inovio Pharmaceuticals (INO) announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia …
In a research report released July 21, Maxim Group analyst Jason Kolbert reaffirmed a Hold rating on IntelliPharmaCeutics (IPCI) with a $3 price target. The analyst commented: “IPCI reported the quarter last …
In a research report published Friday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (SYN) with a $6 price target, which …
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a Buy rating on IsoRay, Inc. (ISR) and increased his price target to $5.
In a research report issued yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Inovio Pharmaceuticals (INO) with an $18 price target, …
In a research report released Friday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Gilead Sciences (GILD) with a price target …
In a research report issued today, IntelliPharmaCeutics International Inc. (IPCI) was downgraded by analyst Jason Kolbert at Maxim Group from Buy to Hold.
Maxim maintains a Buy rating and $7.00 price target on Cesca Therapeutics Inc.
